• linkedin
  • Increase Font
  • Sharebar

    10 More Newly Approved Drugs

    The FDA is having a productive 2017.


    Genetic makeup

    AUSTEDO (deutetrabenazine), Teva

    Indications: A vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

    Dosage: Starting dose is 6 mg once daily. Titrate up at weekly intervals by 6 mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily). Administer total daily dosages of 12 mg or above in two divided doses. Take with food.

    Contraindications: Suicidal, or untreated/inadequately treated depression; hepatic impairment; or concurrent MAOIs, reserpine, or tetrabenazine.

    Read prescribing information here

    Previous ButtonNext Button



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available